标题
Novel CD20 monoclonal antibodies for lymphoma therapy
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 5, Issue 1, Pages 64
出版商
Springer Nature
发表日期
2012-10-11
DOI
10.1186/1756-8722-5-64
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
- (2012) M. S. Czuczman et al. BLOOD
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
- (2012) Myron S. Czuczman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
- (2012) Michinori Ogura et al. CANCER SCIENCE
- Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
- (2012) Andres Forero-Torres et al. CLINICAL CANCER RESEARCH
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD22 therapy in acute lymphoblastic leukaemia
- (2012) Dieter Hoelzer LANCET ONCOLOGY
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Bendamustine: more ammunition in the battle against mantle cell lymphoma
- (2012) Julie E. Chang et al. LEUKEMIA & LYMPHOMA
- Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
- (2011) W. G. Wierda et al. BLOOD
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
- (2011) W. G. Wierda et al. BLOOD
- The future of anti-CD20 monoclonal antibodies: are we making progress?
- (2011) W. Alduaij et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
- (2011) Matthew J. Barth et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia
- (2011) Hong Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies
- (2011) Antonio Gualberto EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion
- (2011) V. Biberacher et al. HAEMATOLOGICA
- A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
- (2011) Craig Reynolds et al. INVESTIGATIONAL NEW DRUGS
- The Four types of Tregs in malignant lymphomas
- (2011) Jing Wang et al. Journal of Hematology & Oncology
- High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
- (2011) Wu ZL et al. Journal of Hematology & Oncology
- Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission
- (2011) F. Buchegger et al. JOURNAL OF NUCLEAR MEDICINE
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
- (2011) Christian Récher et al. LANCET
- Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
- (2011) Bertrand Coiffier et al. LANCET ONCOLOGY
- Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22
- (2011) Weihsu C. Chen et al. LEUKEMIA & LYMPHOMA
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
- (2010) S. M. Jaglowski et al. BLOOD
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- (2010) Kensei Tobinai et al. CANCER SCIENCE
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapy in lymphoma
- (2010) Patrick B Johnston et al. Journal of Hematology & Oncology
- The clinical potential of microRNAs
- (2010) Anuradha Budhu et al. Journal of Hematology & Oncology
- Role of Wnt canonical pathway in hematological malignancies
- (2010) Xueling GE et al. Journal of Hematology & Oncology
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
- (2010) Jiahuai Tan et al. Journal of Hematology & Oncology
- Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
- (2010) David M. Goldenberg et al. LEUKEMIA & LYMPHOMA
- The future of CD20 monoclonal antibody therapy in B-cell malignancies
- (2010) Myron S. Czuczman et al. LEUKEMIA & LYMPHOMA
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD20-Targeted Therapy: The Next Generation of Antibodies
- (2010) Tom van Meerten et al. SEMINARS IN HEMATOLOGY
- Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma
- (2009) B. Esmaeli et al. ANNALS OF ONCOLOGY
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Histone deacetylase inhibitors as anti-neoplastic agents
- (2009) Nicolas Batty et al. CANCER LETTERS
- Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
- (2009) Susumu Uchiyama et al. CANCER SCIENCE
- Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
- (2009) A. M. Al-Katib et al. CLINICAL CANCER RESEARCH
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
- (2009) A. B. Delaloye et al. JOURNAL OF NUCLEAR MEDICINE
- A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study
- (2009) Oliver Weigert et al. LEUKEMIA & LYMPHOMA
- Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
- (2008) J. H. Mendler et al. ANNALS OF ONCOLOGY
- Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
- (2008) Jessica K Altman et al. CURRENT OPINION IN HEMATOLOGY
- Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
- (2008) Victor Y. Yazbeck et al. EXPERIMENTAL HEMATOLOGY
- Lenalidomide for the Treatment of B-Cell Malignancies
- (2008) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
- (2008) Manzurul A. Sikder et al. Current Hematologic Malignancy Reports
- STAT3: A critical transcription activator in angiogenesis
- (2007) Zhong Chen et al. MEDICINAL RESEARCH REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More